Amylin (AMLN) calls are active on renewed takeover chatter. Now, as before (see /color AMLN), Eli Lilly (LLY) has been mentioned as the interested party. The two companies already have an existing relationship with respect to Byetta, an injectable diabetes drug. Shares are reacting to todays chatter, up $1.42 to $32.40 Call volume is outpacing put volume by a margin of more than five to one.